Atrial fibrillation: Difference between revisions
m (Robot: Changing Category:Up-To-Date Cardiology to Category:Up-To-Date cardiology) |
No edit summary |
||
Line 17: | Line 17: | ||
{{CMG}} | {{CMG}} | ||
'''Synonyms and related keywords''' | '''''Synonyms and related keywords:''''' AF, Afib, fib, PAF, paroxysmal afib, Lone fibrillator | ||
==[[Atrial fibrillation overview|Overview]]== | ==[[Atrial fibrillation overview|Overview]]== | ||
Line 25: | Line 25: | ||
==[[Atrial fibrillation epidemiology and demographics|Epidemiology and demographics]]== | ==[[Atrial fibrillation epidemiology and demographics|Epidemiology and demographics]]== | ||
==[[Atrial fibrillation risk factors | Risk Factors]]== | ==[[Atrial fibrillation risk factors|Risk Factors]]== | ||
==[[Atrial fibrillation screening|Screening]]== | |||
==[[Atrial fibrillation diagnosis|Diagnosis]]== | ==[[Atrial fibrillation diagnosis|Diagnosis]]== | ||
[[Atrial fibrillation symptoms|Symptoms | [[Atrial fibrillation symptoms|History and Symptoms]] | [[Atrial fibrillation physical examination|Physical Examination]] | [[Atrial fibrillation laboratory tests|Laboratory Tests]] | [[Atrial fibrillation electrocardiogram|Electrocardiogram]] | [[Atrial fibrillation chest x ray|Chest X ray]] | [[Atrial fibrillation echocardiography or ultrasound|Echocardiography]] | [[Atrial fibrillation other imaging findings#Holter monitoring|Holter monitoring]] | [[Atrial fibrillation other imaging findings#Exercise stress testing|Exercise stress testing]] | ||
==Treatment== | ==[[Atrial fibrillation overview of treatment|Treatment]]== | ||
===[[Atrial fibrillation urgent treatment|Urgent | ===[[Atrial fibrillation urgent treatment|Urgent DC Cardioversion]]=== | ||
===[[Atrial fibrillation | ===Anticoagulation:=== | ||
[[Atrial fibrillation anticoagulation|Anticoagulation Overview]] | [[Warfarin]] | [[Dabigatran]] | [[Dabigatran#Converting from or to Warfarin|Converting from or to Warfarin]] | [[Dabigatran#Converting from or to Parenteral Anticoagulants|Converting from or to Parenteral Anticoagulants]] | |||
=== | =====Dabigatran===== | ||
[[ | [[dabigatran#Dosing|Dosing]] | [[Dabigatran#Surgery and Interventions|Discontinuation for Surgery and Interventions]] | [[Dabigatran#WARNINGS AND PRECAUTIONS| Warnings and Precautions]] | [[Dabigatran#Adverse Reactions|Adverse Reactions]] | [[Dabigatran#Use in Specific Populations|Use in Specific Populations Such as Pregnancy]] | [[Dabigatran#Overdosage|Overdosage]] | [[Clinical Pharmacology of Dabigatran|Clinical Pharmacology]] | [[FDA Review of Data From the RE-LY Trial on September 20th, 2010|FDA Review of the RE-LY Data]] | [[A comparison of the RE-LY and Rocket AF Trials ]] | [[Estimates of Cost Per Year of Life Saved for Dabigatran]] | ||
[[ | ===[[Atrial fibrillation rate control|Rate control]]=== | ||
===[[Atrial fibrillation maintenance of sinus rhythm|Maintenance of Sinus Rhythm]]=== | |||
=== | ===Surgical options:=== | ||
[[Atrial fibrillation | [[Atrial fibrillation cardioversion|Cardioversion]] | [[Atrial fibrillation invasive treatment#Radiofrequency ablation|Radiofrequency ablation]] | [[Atrial fibrillation percutaneous coronary intervention|PCI in Afib]] | [[Atrial fibrillation surgical treatment|Maze Open Heart Surgery]] | ||
==Special Considerations== | |||
[[Postoperative atrial fibrillation|Postoperative AF]] | [[Postoperative atrial fibrillation|Postoperative AF]] | [[Atrial fibrillation acute myocardial infarction|Acute Myocardial Infarction]] | [[Atrial fibrillation Wolff-Parkinson-White preexcitation syndromes|Wolff-Parkinson-White Preexcitation Syndromes]] | [[Atrial fibrillation hypertrophic cardiomyopathy|Hypertrophic Cardiomyopathy]] | [[Atrial fibrillation hyperthyroidism|Hyperthyroidism]] | [[Atrial fibrillation pulmonary diseases|Pulmonary Diseases]] | [[Atrial fibrillation pregnancy|Pregnancy]] | ||
==[[Atrial fibrillation | ==[[Atrial fibrillation secondary prevention|Secondary Prevention]]== | ||
==[[Atrial fibrillation clinical trial data| | ==[[Atrial fibrillation clinical trial data|Supportive Trial Data]]== | ||
==Vote on and Suggest Revisions to the Current Guidelines== | ==Vote on and Suggest Revisions to the Current Guidelines== |
Revision as of 15:00, 3 April 2012
Atrial fibrillation | |
ICD-10 | I48 |
---|---|
ICD-9 | 427.31 |
DiseasesDB | 1065 |
MedlinePlus | 000184 |
Atrial Fibrillation Microchapters | |
Special Groups | |
---|---|
Diagnosis | |
Treatment | |
Cardioversion | |
Anticoagulation | |
Surgery | |
Case Studies | |
Atrial fibrillation On the Web | |
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and related keywords: AF, Afib, fib, PAF, paroxysmal afib, Lone fibrillator
Overview
Pathophysiology
Epidemiology and demographics
Risk Factors
Screening
Diagnosis
History and Symptoms | Physical Examination | Laboratory Tests | Electrocardiogram | Chest X ray | Echocardiography | Holter monitoring | Exercise stress testing
Treatment
Urgent DC Cardioversion
Anticoagulation:
Anticoagulation Overview | Warfarin | Dabigatran | Converting from or to Warfarin | Converting from or to Parenteral Anticoagulants
Dabigatran
Dosing | Discontinuation for Surgery and Interventions | Warnings and Precautions | Adverse Reactions | Use in Specific Populations Such as Pregnancy | Overdosage | Clinical Pharmacology | FDA Review of the RE-LY Data | A comparison of the RE-LY and Rocket AF Trials | Estimates of Cost Per Year of Life Saved for Dabigatran
Rate control
Maintenance of Sinus Rhythm
Surgical options:
Cardioversion | Radiofrequency ablation | PCI in Afib | Maze Open Heart Surgery
Special Considerations
Postoperative AF | Acute Myocardial Infarction | Wolff-Parkinson-White Preexcitation Syndromes | Hypertrophic Cardiomyopathy | Hyperthyroidism | Pulmonary Diseases | Pregnancy
Secondary Prevention
Supportive Trial Data
Vote on and Suggest Revisions to the Current Guidelines
Guideline Resources
- 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation [2]
- ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter [3]
Related Chapters
External links
- American Heart Association's page on atrial fibrillation
- Atrial fibrillation
- Bandolier: Evidence-based medicine resource on atrial fibrillation
References
- ↑ Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. (2006) ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114 (7):e257-354. DOI:10.1161/CIRCULATIONAHA.106.177292 PMID: 16908781
- ↑ Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123 (10):e269-367. DOI:10.1161/CIR.0b013e318214876d PMID: 21382897
- ↑ Estes NA, Halperin JL, Calkins H, Ezekowitz MD, Gitman P, Go AS et al. (2008) ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm Society. Circulation 117 (8):1101-20. DOI:10.1161/CIRCULATIONAHA.107.187192 PMID: 18283199
de:Vorhofflimmern it:Fibrillazione atriale nl:Boezemfibrilleren no:Atrieflimmer fi:Eteisvärinä